STAT3 and ovarian carcinoma: Continuous activation of the IL-6/STAT3 signaling pathway has been detected in liver cancer, lung cancer, breast cancer, ovarian cancer, gastric cancer and other cancers (1–5), and IL-6/STAT3 may be a promising biotarget to prevent and treat cancer.